Andrew J. Wagner, MD, PhD

MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts, United States

Disclosure information not submitted.

Presentation(s):

• Paper 43 - BRIGIMADLIN VERSUS STANDARD-OF-CARE DOXORUBICIN AS FIRST-LINE TREATMENT IN PATIENTS WITH ADVANCED DEDIFFERENTIATED LIPOSARCOMA (DDLPS): BRIGHTLINE-1

  Friday, November 15, 2024
  9:00 AM – 10:00 AM PST

• Paper 79 - PHASE 3 STUDY OF IVOSIDENIB VS PLACEBO IN LOCALLY ADVANCED OR METASTATIC IDH1-MUTANT CONVENTIONAL CHONDROSARCOMA UNTREATED OR PREVIOUSLY TREATED WITH 1 SYSTEMIC TREATMENT REGIMEN (CHONQUER)

  Saturday, November 16, 2024
  9:00 AM – 10:00 AM PST

• Paper 105 - EFFICACY, SAFETY, AND PATIENT-REPORTED OUTCOMES OF VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: RESULTS FROM THE MOTION PHASE 3 TRIAL

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST

• Paper 106 - SAFETY, EFFICACY, AND PATIENT-REPORTED OUTCOMES WITH VIMSELTINIB IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR WHO RECEIVED PRIOR ANTI-COLONY-STIMULATING FACTOR 1 THERAPY: ONGOING PHASE 2 STUDY

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST

• Paper 107 - PEXIDARTINIB USE IN PATIENTS WITH TENOSYNOVIAL GIANT CELL TUMOR: AN ANALYSIS OF THE PHASE III RANDOMIZED ENLIVEN CLINICAL TRIAL ACCORDING TO SURGICAL HISTORY

  Saturday, November 16, 2024
  3:30 PM – 4:30 PM PST